These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 38724518)

  • 1. Contemporary HIV-1 consensus Env with AI-assisted redesigned hypervariable loops promote antibody binding.
    Bai H; Lewitus E; Li Y; Thomas PV; Zemil M; Merbah M; Peterson CE; Thuraisamy T; Rees PA; Hajduczki A; Dussupt V; Slike B; Mendez-Rivera L; Schmid A; Kavusak E; Rao M; Smith G; Frey J; Sims A; Wieczorek L; Polonis V; Krebs SJ; Ake JA; Vasan S; Bolton DL; Joyce MG; Townsley S; Rolland M
    Nat Commun; 2024 May; 15(1):3924. PubMed ID: 38724518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of Novel Structural Determinants in MW965 Env That Regulate the Neutralization Phenotype and Conformational Masking Potential of Primary HIV-1 Isolates.
    Qualls ZM; Choudhary A; Honnen W; Prattipati R; Robinson JE; Pinter A
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope.
    Schoofs T; Barnes CO; Suh-Toma N; Golijanin J; Schommers P; Gruell H; West AP; Bach F; Lee YE; Nogueira L; Georgiev IS; Bailer RT; Czartoski J; Mascola JR; Seaman MS; McElrath MJ; Doria-Rose NA; Klein F; Nussenzweig MC; Bjorkman PJ
    Immunity; 2019 Jun; 50(6):1513-1529.e9. PubMed ID: 31126879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
    Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
    J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Rare Mutation in an Infant-Derived HIV-1 Envelope Glycoprotein Alters Interprotomer Stability and Susceptibility to Broadly Neutralizing Antibodies Targeting the Trimer Apex.
    Mishra N; Sharma S; Dobhal A; Kumar S; Chawla H; Singh R; Das BK; Kabra SK; Lodha R; Luthra K
    J Virol; 2020 Sep; 94(19):. PubMed ID: 32669335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination with Glycan-Modified HIV NFL Envelope Trimer-Liposomes Elicits Broadly Neutralizing Antibodies to Multiple Sites of Vulnerability.
    Dubrovskaya V; Tran K; Ozorowski G; Guenaga J; Wilson R; Bale S; Cottrell CA; Turner HL; Seabright G; O'Dell S; Torres JL; Yang L; Feng Y; Leaman DP; Vázquez Bernat N; Liban T; Louder M; McKee K; Bailer RT; Movsesyan A; Doria-Rose NA; Pancera M; Karlsson Hedestam GB; Zwick MB; Crispin M; Mascola JR; Ward AB; Wyatt RT
    Immunity; 2019 Nov; 51(5):915-929.e7. PubMed ID: 31732167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Bispecific Antibody That Simultaneously Recognizes the V2- and V3-Glycan Epitopes of the HIV-1 Envelope Glycoprotein Is Broader and More Potent than Its Parental Antibodies.
    Davis-Gardner ME; Alfant B; Weber JA; Gardner MR; Farzan M
    mBio; 2020 Jan; 11(1):. PubMed ID: 31937648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stabilization of the V2 loop improves the presentation of V2 loop-associated broadly neutralizing antibody epitopes on HIV-1 envelope trimers.
    de Taeye SW; Go EP; Sliepen K; de la Peña AT; Badal K; Medina-Ramírez M; Lee WH; Desaire H; Wilson IA; Moore JP; Ward AB; Sanders RW
    J Biol Chem; 2019 Apr; 294(14):5616-5631. PubMed ID: 30728245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in Structure and Antigenicity of HIV-1 Env Trimers Resulting from Removal of a Conserved CD4 Binding Site-Proximal Glycan.
    Liang Y; Guttman M; Williams JA; Verkerke H; Alvarado D; Hu SL; Lee KK
    J Virol; 2016 Oct; 90(20):9224-36. PubMed ID: 27489265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Immunogenicity of Evolved V1V2-Deleted HIV-1 Envelope Glycoprotein Trimers.
    Bontjer I; Melchers M; Tong T; van Montfort T; Eggink D; Montefiori D; Olson WC; Moore JP; Binley JM; Berkhout B; Sanders RW
    PLoS One; 2013; 8(6):e67484. PubMed ID: 23840716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional Stability of HIV-1 Envelope Trimer Affects Accessibility to Broadly Neutralizing Antibodies at Its Apex.
    Gift SK; Leaman DP; Zhang L; Kim AS; Zwick MB
    J Virol; 2017 Dec; 91(24):. PubMed ID: 28978711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of susceptibility of HIV-1 CRF01_AE variants to neutralization by a panel of broadly neutralizing antibodies.
    Wang H; Yuan T; Li T; Li Y; Qian F; Zhu C; Liang S; Hoffmann D; Dittmer U; Sun B; Yang R
    Arch Virol; 2018 Dec; 163(12):3303-3315. PubMed ID: 30196320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced Potency and Incomplete Neutralization of Broadly Neutralizing Antibodies against Cell-to-Cell Transmission of HIV-1 with Transmitted Founder Envs.
    Li H; Zony C; Chen P; Chen BK
    J Virol; 2017 May; 91(9):. PubMed ID: 28148796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Glycan Hole Area of HIV-1 Envelope Trimers Contributes Prominently to the Induction of Autologous Neutralization.
    Schorcht A; Cottrell CA; Pugach P; Ringe RP; Han AX; Allen JD; van den Kerkhof TLGM; Seabright GE; Schermer EE; Ketas TJ; Burger JA; van Schooten J; LaBranche CC; Ozorowski G; de Val N; Bader DLV; Schuitemaker H; Russell CA; Montefiori DC; van Gils MJ; Crispin M; Klasse PJ; Ward AB; Moore JP; Sanders RW
    J Virol; 2022 Jan; 96(1):e0155221. PubMed ID: 34669426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralizing Antibody Responses Induced by HIV-1 Envelope Glycoprotein SOSIP Trimers Derived from Elite Neutralizers.
    Schorcht A; van den Kerkhof TLGM; Cottrell CA; Allen JD; Torres JL; Behrens AJ; Schermer EE; Burger JA; de Taeye SW; Torrents de la Peña A; Bontjer I; Gumbs S; Ozorowski G; LaBranche CC; de Val N; Yasmeen A; Klasse PJ; Montefiori DC; Moore JP; Schuitemaker H; Crispin M; van Gils MJ; Ward AB; Sanders RW
    J Virol; 2020 Nov; 94(24):. PubMed ID: 32999024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells.
    Cohen YZ; Lorenzi JCC; Seaman MS; Nogueira L; Schoofs T; Krassnig L; Butler A; Millard K; Fitzsimons T; Daniell X; Dizon JP; Shimeliovich I; Montefiori DC; Caskey M; Nussenzweig MC
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VSV-Displayed HIV-1 Envelope Identifies Broadly Neutralizing Antibodies Class-Switched to IgG and IgA.
    Jia M; Liberatore RA; Guo Y; Chan KW; Pan R; Lu H; Waltari E; Mittler E; Chandran K; Finzi A; Kaufmann DE; Seaman MS; Ho DD; Shapiro L; Sheng Z; Kong XP; Bieniasz PD; Wu X
    Cell Host Microbe; 2020 Jun; 27(6):963-975.e5. PubMed ID: 32315598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 tat promotes integrin-mediated HIV transmission to dendritic cells by binding Env spikes and competes neutralization by anti-HIV antibodies.
    Monini P; Cafaro A; Srivastava IK; Moretti S; Sharma VA; Andreini C; Chiozzini C; Ferrantelli F; Cossut MR; Tripiciano A; Nappi F; Longo O; Bellino S; Picconi O; Fanales-Belasio E; Borsetti A; Toschi E; Schiavoni I; Bacigalupo I; Kan E; Sernicola L; Maggiorella MT; Montin K; Porcu M; Leone P; Leone P; Collacchi B; Palladino C; Ridolfi B; Falchi M; Macchia I; Ulmer JB; Buttò S; Sgadari C; Magnani M; Federico MP; Titti F; Banci L; Dallocchio F; Rappuoli R; Ensoli F; Barnett SW; Garaci E; Ensoli B
    PLoS One; 2012; 7(11):e48781. PubMed ID: 23152803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D.
    McGuire AT; Glenn JA; Lippy A; Stamatatos L
    J Virol; 2014 Mar; 88(5):2645-57. PubMed ID: 24352455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antigenicity and immunogenicity of HIV-1 gp140 with different combinations of glycan mutation and V1/V2 region or V3 crown deletion.
    Fu M; Hu K; Hu H; Ni F; Du T; Shattock RJ; Hu Q
    Vaccine; 2019 Dec; 37(51):7501-7508. PubMed ID: 31564450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.